Overview

Evaluation of DHA for the Treatment of PSC

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The researches aim to study the effects of DHA (component of fish oil) on patients with Primary Sclerosing Cholangitis (PSC). Our hypothesis is that DHA might reverse the problems associated with PSC.
Phase:
Phase 1
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)